Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality patient
care. It is applicable to specialists, primary care practitioners, and providers at all levels. is
Guideline should not be considered exclusive of other methods of care reasonably directed at
obtaining the same results. e ultimate judgment concerning the propriety of any course of
conduct must be made by the clinician aer consideration of each individual patient situation.
Neither IGC, the medical associations, nor the authors endorse any product or service associated
with the distributor of this clinical reference tool.
Abbreviations
apo, apolipoprotein; ASCVD, atherosclerotic cardiovascular disease; ATP, Adult
Treatment Panel; CHD, coronary heart disease; CKD, chronic kidney disease; CVD,
cerebrovascular disease; DHA, docosahexaenoic acid; DM, diabetes mellitus; EE, ethyl
esters; EPA, eicosapentaenoic acid; FDA, US Food and Drug Administration; FH,
familial hypercholesterolemia; GFR, glomerular filtration rate; GI, gastrointestinal;
HDL-C, high-density lipoprotein cholesterol; HIV, human immunodeficiency virus;
LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; LFT,
liver function tests; MI, myocardial infarction; N/A, not applicable; NLA, National
Lipid Association; Non-HDL-C, non-high-density lipoprotein cholesterol; PO, by
mouth; RCTs, randomized controlled trials; RDN, registered dietitian nutritionist; Rx,
treatment; subcut, subutaneous; TG, triglycerides; total-C, total cholesterol; VLDL,
very low density lipoprotein; VLDL-C, very low density lipoprotein cholesterol; WHO,
World Health Organization
Source
Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association Recommendations for
Patient-Centered Management of Dyslipidemia: Part 1-Executive Summary J Clin Lipidol
2014; 8:473–88
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
For additional copies: info@GuidelineCentral.com
Copyright © 2014 All rights reserved
NLADYS14113f
